All In Biotech

Drug Trial Radar · NCT06470828

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Jul 2, 2024

Primary completion

Jun 3, 2025

Study completion Jun 3, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn how effective TAK-861 (oveporexton) is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 (oveporexton) is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 (oveporexton) has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms, and daily life functions; and to learn about the safety of TAK-861 (oveporexton).

Conditions

  • Narcolepsy Type 1

Interventions

  • OveporextonDrug

    Oral tablet.

  • PlaceboDrug

    OVE-matching placebo tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake TrialsTime frame: Baseline, Week 12

Locations

53 sites in 11 countries. Site status is shown where the registry gives one.

  • Takeda Site 48

    Phoenix, Arizona

  • Takeda Site 39

    Redwood City, California

  • Takeda Site 31

    Santa Ana, California

  • Takeda Site 18

    Upland, California

  • Takeda Site 4

    Orlando, Florida

  • Takeda Site 3

    Atlanta, Georgia

  • Takeda Site 45

    Boston, Massachusetts

  • Takeda Site 5

    St Louis, Missouri

  • Takeda Site 2

    Denver, North Carolina

  • Takeda Site 6

    Cincinnati, Ohio

  • Takeda Site 42

    Cleveland, Ohio

  • Takeda Site 49

    Danville, Pennsylvania

  • Takeda Site 1

    Columbia, South Carolina

  • Takeda Site 44

    Dallas, Texas

  • Takeda Site 10

    Norfolk, Virginia

  • Takeda Site 21

    Ottawa, Ontario, Canada

  • Takeda Site 11

    Toronto, Ontario, Canada

  • Takeda Site 50

    Montreal, Quebec, Canada

  • Takeda Site 40

    Lyon, France

  • Takeda Site 29

    Paris, France

  • Takeda Site 25

    Montpellier, Herault, France

  • Takeda Site 43

    Toulouse, Midi-Pyrenees, France

  • Takeda Site 34

    Berlin, Germany

  • Takeda Site 26

    Schwerin, Germany

  • Takeda Site 47

    Regensberg, Bavaria, Germany

  • Takeda Site 30

    Bologna, Italy

  • Takeda Site 32

    Rome, Lazio, Italy

  • Takeda Site 16

    Kurume-shi, Fukuka-Ken, Japan

  • Takeda Site 13

    Kitakyushu-shi, Fukuoka, Japan

  • Takeda Site 14

    Fukuoka, Fukuoka-Shi Hakata-Ku, Japan

  • Takeda Site 9

    Kohoku, Kanagawa, Japan

  • Takeda Site 7

    Kumamoto, Kumamoto, Japan

  • Takeda Site 17

    Isahaya-shi, Nagasaki, Japan

  • Takeda Site 15

    Urasoe-Shi, Okinawa, Japan

  • Takeda Site 12

    Yodogawa, Osaka, Japan

  • Takeda Site 8

    Bunkyo-ku, Tokyo, Japan

  • Takeda Site 19

    Kodaira-shi, Tokyo, Japan

  • Takeda Site 20

    Shibuya-ku, Tokyo, Japan

  • Takeda Site 28

    Zwolle, Netherlands

  • Takeda Site 33

    Oslo, Norway

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.